Sangamo Therapeutics, Inc. - SGMO STOCK NEWS

Sangamo Therapeutics has reported updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. As of November 9, 2021, the treatment was well tolerated across five patients, with α-Gal A activity significantly elevated in four patients (3-15 times above normal). The fifth patient in the third cohort showed mean normal levels at week 2. Notably, there were no serious adverse events. Sangamo plans to advance to Phase 3 following the completion of the current study, with further results expected throughout 2022.

Sangamo Therapeutics, Inc. announced that Sanofi will transition its rights for SAR445136, a gene-edited cell therapy for sickle cell disease, back to Sangamo in the first half of 2022. This change follows Sanofi's decision to terminate their collaboration, citing a shift in strategy. The Phase 1/2 PRECIZN-1 study of SAR445136 is expected to finish as planned, with final patient dosing anticipated in Q3 2022. Preliminary data showed no treatment-related adverse events, and treated patients did not require blood transfusions post-engraftment.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced that management will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10 at 7:00 a.m. Eastern Time. The presentation can be accessed via the company's website in the Investors and Media section and will be available for viewing post-event. Sangamo focuses on genomic medicine using proprietary zinc finger genome engineering technologies to develop new treatments for diseases lacking adequate options.

Pfizer (NYSE: PFE) and Sangamo Therapeutics (NASDAQ: SGMO) have released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy for severe hemophilia A. At 104 weeks, patients in the highest dose cohort exhibited a mean factor VIII activity of 25.4% with no annualized bleeding in the first year post-infusion. However, the Phase 3 AFFINE trial has encountered a clinical hold by the FDA following observations of elevated FVIII levels in treated patients. The ongoing studies aim to evaluate long-term efficacy and safety of this investigational therapy.

Sangamo Therapeutics announced positive preliminary data from its Phase 1/2 PRECIZN-1 study of SAR445136, a gene-edited cell therapy for sickle cell disease (SCD). All four treated patients showed increased total hemoglobin and fetal hemoglobin, with none requiring blood transfusions post-engraftment. The longest-treated patient was followed for 91 weeks. The safety profile was favorable, with no adverse events linked to SAR445136. These findings highlight the therapeutic potential of zinc finger nuclease technology in addressing unmet needs in SCD.

Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in several upcoming investor conferences. Management will present at the Barclays Gene Editing & Gene Therapy Summit on November 15 at 10:30 a.m. Eastern Time, followed by the Stifel 2021 Virtual Healthcare Conference on the same day at 3:20 p.m. Eastern Time. Additionally, they will participate in the Jefferies London Healthcare Conference on November 16 at 8:40 a.m. Eastern Time. Presentations will be webcasted live and available later on Sangamo's website.

Sangamo Therapeutics (SGMO) reported its Q3 2021 financial results, revealing a net loss of $47.7 million or $0.33 per share, a significant increase from a loss of $1.6 million in Q3 2020. Revenue dropped to $28.6 million, down from $57.8 million, mainly due to reduced collaboration revenue with Pfizer. Key clinical updates include positive data from its Fabry disease and hemophilia A programs, with plans for a Phase 3 trial for Fabry disease. Additionally, preliminary results for its sickle cell disease therapy will be shared at the ASH meeting in December.

Sangamo Therapeutics has announced promising preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. All four patients in the initial cohorts showed above-normal α-Gal A activity, maintained for up to one year. The company is planning a Phase 3 trial following these results, with one patient withdrawing from enzyme replacement therapy due to stable enzyme activity. There were no Grade 2 or higher adverse events reported.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced the release date for its third quarter 2021 financial results, set for November 4, 2021. Following the release, a conference call is scheduled at 9:15 a.m. ET, open to the public through telephone and webcast. Key details include dial-in numbers and a conference ID for participants. Sangamo is a clinical-stage biopharmaceutical firm focused on genomic medicines, leveraging proprietary technology to develop solutions for patients with unmet medical needs. For more information, visit sangamo.com.